A Phase II, Multicenter, Open-Labeled Study of Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma
- Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic
- All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung
metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA
type A1, A2, or B35.
- Patients must have adequate organ function and an estimated life expectancy of at
least 3 months.
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration